X

Trial Profile

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy: a Randomized Phase II Proof-of-concept Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 02 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Proof of concept; Therapeutic Use
Acronyms BASALT

Most Recent Events

29 Jul 2024 Planned End Date changed from 1 Jan 2024 to 10 Apr 2028.
24 Oct 2023 Primary endpoint(Efficacy defined as pathological response to chemoradiotherapy according to the Mandard criteria) has not been met.
24 Oct 2023 Status changed from active, no longer recruiting to discontinued due to safety concerns.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com